Literature DB >> 26004559

Glucose-6-phosphate dehydrogenase deficiency and Alzheimer's disease: Partners in crime? The hypothesis.

N Nuray Ulusu1.   

Abstract

Alzheimer's disease is a multifaceted brain disorder which involves various coupled irreversible, progressive biochemical reactions that significantly reduce quality of life as well as the actual life expectancy. Aging, genetic predispositions, head trauma, diabetes, cardiovascular disease, deficiencies in insulin signaling, dysfunction of mitochondria-associated membranes, cerebrovascular changes, high cholesterol level, increased oxidative stress and free radical formation, DNA damage, disturbed energy metabolism, and synaptic dysfunction, high blood pressure, obesity, dietary habits, exercise, social engagement, and mental stress are noted among the risk factors of this disease. In this hypothesis review I would like to draw the attention on glucose-6-phosphate dehydrogenase deficiency and its relationship with Alzheimer's disease. This enzymopathy is the most common human congenital defect of metabolism and defined by decrease in NADPH+H(+) and reduced form of glutathione concentration and that might in turn, amplify oxidative stress due to essentiality of the enzyme. This most common enzymopathy may manifest itself in severe forms, however most of the individuals with this deficiency are not essentially symptomatic. To understand the sporadic Alzheimer's disease, the writer of this paper thinks that, looking into a crystal ball might not yield much of a benefit but glucose-6-phosphate dehydrogenase deficiency could effortlessly give some clues.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26004559     DOI: 10.1016/j.mehy.2015.05.006

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  7 in total

1.  Is glucose-6-phosphate dehydrogenase enzyme deficiency a factor in Coronavirus-19 (COVID-19) infections and deaths?

Authors:  Duygu Aydemir; Nuriye Nuray Ulusu
Journal:  Pathog Glob Health       Date:  2020-04-14       Impact factor: 2.894

Review 2.  Reduced nicotinamide adenine dinucleotide phosphate in redox balance and diseases: a friend or foe?

Authors:  Nirmala Koju; Zheng-Hong Qin; Rui Sheng
Journal:  Acta Pharmacol Sin       Date:  2022-01-11       Impact factor: 7.169

3.  Biological sex and DNA repair deficiency drive Alzheimer's disease via systemic metabolic remodeling and brain mitochondrial dysfunction.

Authors:  Tyler G Demarest; Vijay R Varma; Darlene Estrada; Mansi Babbar; Sambuddha Basu; Uma V Mahajan; Ruin Moaddel; Deborah L Croteau; Madhav Thambisetty; Mark P Mattson; Vilhelm A Bohr
Journal:  Acta Neuropathol       Date:  2020-04-24       Impact factor: 17.088

4.  Evaluation of Renal Function in Alzheimer's Disease and Geriatric Patients: Results from a Turkish Two-center Study.

Authors:  Zubeyde Erbayraktar; Ahmet Turan Evlice; Gokhan Yilmaz; Canan Yazici; Gorsev Yener; Nuriye Nuray Ulusu
Journal:  J Med Biochem       Date:  2017-01-25       Impact factor: 3.402

5.  Comparison of Spectrophotometric and Fluorimetric Methods in Evaluation of Biotinidase Deficiency.

Authors:  Sevgin Özlem Işeri-Erten; Zeliha Günnur Dikmen; Nuriye Nuray Ulusu
Journal:  J Med Biochem       Date:  2016-05-09       Impact factor: 3.402

6.  Effects of Timolol Treatment on Pancreatic Antioxidant Enzymes in Streptozotocin-induced Diabetic Rats: An Experimental and Computational Study.

Authors:  Nuriye Nuray Ulusu; Muslum Gok; Burak Erman; Belma Turan
Journal:  J Med Biochem       Date:  2019-05-11       Impact factor: 3.402

7.  Antioxidant SMe1EC2 modulates pentose phosphate pathway and glutathione-dependent enzyme activities in tissues of aged diabetic rats.

Authors:  Nuray Nuriye Ulusu; Müslüm Gök; Arzu Ayşe Sayin Şakul; Nuray Ari; Milan Stefek; Çimen Karasu
Journal:  Interdiscip Toxicol       Date:  2018-03-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.